Randomized Controlled Trial

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.

Pain. 2016 Jan 1; 157 (1): 264-272.
Article

(432) Respiratory safety signal with oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), vs morphine: a safety analysis of a Phase 2b randomized clinical trial.

J Pain. 2016 Apr 1; 17 (4S): S82.
Article

(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trials.

J Pain. 2016 Apr 1; 17 (4S): S82-S83.